Breakthrough in Cancer Treatment: New Light-Based Therapy Shows Promise
Scientists have made a significant breakthrough in the fight against cancer, developing a new light-based therapy that can selectively target and kill tumor cells while leaving healthy tissue intact. The innovative treatment uses near-infrared (NIR) light to convert into heat, which is then absorbed by specialized nanomaterials called tin oxide (SnOx) nanoflakes.
These tiny particles are engineered to accumulate specifically in tumor tissues, where they can be targeted with NIR light at a specific wavelength. This process triggers the release of heat that destroys cancer cells without harming healthy skin cells or other surrounding tissue.
The research team from the University of Texas at Austin and the University of Porto in Portugal conducted experiments using a proprietary system based on NIR-LEDs to irradiate SnOx nanoflakes-treated cancer cells. The results were impressive, with up to 92% of skin cancer cells and 50% of colorectal cancer cells killed within just 30 minutes of exposure.
This breakthrough is a major step forward in the development of photothermal therapies, which are non-invasive procedures that use light to heat up cancer cells for destruction. The new technology offers greater thermal efficiency, biocompatibility, and affordability than existing materials used in these treatments.
According to the researchers, their goal was not only to create an effective treatment but also one that is safe and accessible to patients worldwide, particularly those in areas where access to specialized equipment is limited. They envision a future where this technology can be used to treat skin cancers at home, using a portable device to irradiate and destroy any remaining cancer cells.
While further biological and clinical studies are still required, the potential of this new light-based therapy is significant. If successful, it could provide a game-changing alternative to traditional chemotherapy and radiotherapy treatments, offering patients fewer side effects and lower costs.
Scientists have made a significant breakthrough in the fight against cancer, developing a new light-based therapy that can selectively target and kill tumor cells while leaving healthy tissue intact. The innovative treatment uses near-infrared (NIR) light to convert into heat, which is then absorbed by specialized nanomaterials called tin oxide (SnOx) nanoflakes.
These tiny particles are engineered to accumulate specifically in tumor tissues, where they can be targeted with NIR light at a specific wavelength. This process triggers the release of heat that destroys cancer cells without harming healthy skin cells or other surrounding tissue.
The research team from the University of Texas at Austin and the University of Porto in Portugal conducted experiments using a proprietary system based on NIR-LEDs to irradiate SnOx nanoflakes-treated cancer cells. The results were impressive, with up to 92% of skin cancer cells and 50% of colorectal cancer cells killed within just 30 minutes of exposure.
This breakthrough is a major step forward in the development of photothermal therapies, which are non-invasive procedures that use light to heat up cancer cells for destruction. The new technology offers greater thermal efficiency, biocompatibility, and affordability than existing materials used in these treatments.
According to the researchers, their goal was not only to create an effective treatment but also one that is safe and accessible to patients worldwide, particularly those in areas where access to specialized equipment is limited. They envision a future where this technology can be used to treat skin cancers at home, using a portable device to irradiate and destroy any remaining cancer cells.
While further biological and clinical studies are still required, the potential of this new light-based therapy is significant. If successful, it could provide a game-changing alternative to traditional chemotherapy and radiotherapy treatments, offering patients fewer side effects and lower costs.